KR-31543

a neuroprotective agent for ischemia-reperfusion damage

Also Known As:

(2S,3R,4S)-6-amino-4-(N-(4-chlorophenyl)-N-(2-methyl-2H-tetrazol-5-ylmethyl)amino)-3,4-dihydro-2-dimethoxymethyl-3-hydroxy-2-methyl-2H-1-benzopyran

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Tetrazoles: 14
      - KR-31543: 4
  - Pyrans: 130
    - Benzopyrans: 195
      - KR-31543: 4
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzopyrans: 195
      - KR-31543: 4

Experts

1.	Yoo, Sung-Eun: 3 articles (12/2012 - 10/2002)
2.	Lim, Hong: 3 articles (02/2004 - 10/2002)
3.	Ji, Hye Young: 2 articles (02/2004 - 10/2002)
4.	Lee, Dong Ha: 2 articles (02/2004 - 10/2002)
5.	Lee, Hye Suk: 2 articles (02/2004 - 10/2002)
6.	Lee, Seung-Seok: 2 articles (02/2004 - 10/2002)
7.	Choi, Jae-Hoon: 1 article (12/2012)
8.	Kim, Sun-Ok: 1 article (12/2012)
9.	Oh, Goo Taeg: 1 article (12/2012)
10.	Yoo, Ji-Young: 1 article (12/2012)

Related Diseases

1.	Reperfusion Injury 01/01/2003 - "The purpose of this study was to report dose-independent pharmacokinetics of KR-31543, a new neuroprotective agent for ischemia-reperfusion damage, after intravenous (iv) and oral (po) administration and first-pass effects after iv, intraportal, intragastric, and intraduodenal administration in rats. " 10/01/2002 - "Metabolism of a new neuroprotective agent for ischemia-reperfusion damage, KR-31543 in the rat using liquid chromatography/electrospray mass spectrometry." 01/01/2003 - "Dose-independent pharmacokinetics of a new neuroprotective agent for ischemia-reperfusion damage, KR-31543, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects." 02/01/2004 - "KR-31543, (2S,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(2-methyl-2H-tetrazol-5-ylmethyl)amino]-3,4-dihydro-2-dimethoxymethyl-3-hydroxy-2-methyl-2H-1-benzopyran, is a new neuroprotective agent for preventing ischemia-reperfusion damage. " 10/01/2002 - "KR-31543, (2S,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(2-methyl-2H-tetrazol-5-ylmethyl)amino]-3,4-dihydro-2-dimethoxymethyl-3-hydroxy-2-methyl-2H-1-benzopyran is a new neuroprotective agent for ischemia-reperfusion damage. "
2.	Ischemia 01/01/2003 - "The purpose of this study was to report dose-independent pharmacokinetics of KR-31543, a new neuroprotective agent for ischemia-reperfusion damage, after intravenous (iv) and oral (po) administration and first-pass effects after iv, intraportal, intragastric, and intraduodenal administration in rats. " 10/01/2002 - "Metabolism of a new neuroprotective agent for ischemia-reperfusion damage, KR-31543 in the rat using liquid chromatography/electrospray mass spectrometry." 01/01/2003 - "Dose-independent pharmacokinetics of a new neuroprotective agent for ischemia-reperfusion damage, KR-31543, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects." 02/01/2004 - "KR-31543, (2S,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(2-methyl-2H-tetrazol-5-ylmethyl)amino]-3,4-dihydro-2-dimethoxymethyl-3-hydroxy-2-methyl-2H-1-benzopyran, is a new neuroprotective agent for preventing ischemia-reperfusion damage. " 10/01/2002 - "KR-31543, (2S,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(2-methyl-2H-tetrazol-5-ylmethyl)amino]-3,4-dihydro-2-dimethoxymethyl-3-hydroxy-2-methyl-2H-1-benzopyran is a new neuroprotective agent for ischemia-reperfusion damage. "
3.	Atherosclerosis 12/31/2012 - "Taken together, these results show that KR-31543 has anti-inflammatory properties on human monocytes and endothelial cells, and inhibits fatty streak lesion formation in mouse model of atherosclerosis, suggesting the potential of KR-31543 for the treatment for atherosclerosis." 12/31/2012 - "KR-31543 reduces the production of proinflammatory molecules in human endothelial cells and monocytes and attenuates atherosclerosis in mouse model."

Related Drugs and Biologics

1.	Neuroprotective Agents
2.	Benzopyrans

Related Therapies and Procedures

1.	Oral Administration